Vertex Pharmaceuticals Incorporated VRTX
Healthcare · Biotechnology · United States · S&P 500
Based on the available data, Vertex Pharmaceuticals Incorporated gets an algorithmic score of 76/100. It trades at 526.73 $, with a bullish technical trend (RSI 53.5) and 28.7% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High ROE (23.5%): generates strong profit on equity.
- High net margin (35.0%): pricing power / competitive advantage.
- Sustained revenue growth (10.4% compound annual).
- Low-debt balance sheet.
- Low beta (0.30): defensive profile.
Weaknesses
- —
Fundamentals
| P/E | 30.62 |
| Forward P/E | 26.21 |
| PEG | 1.90 |
| P/B | 6.59 |
| EV/EBITDA | 25.02 |
| P/S | 10.60 |
| ROE % | 23.54 |
| ROA % | 11.93 |
| Gross margin % | 54.96 |
| Operating margin % | 38.05 |
| Net margin % | 35.00 |
| Revenue growth % (y/y) | 12.50 |
| Earnings growth % (y/y) | 8.00 |
| Revenue CAGR % | 10.35 |
| Earnings CAGR % | 5.97 |
| Debt/Equity % | 9.77 |
| Current ratio | 3.19 |
| FCF yield % | 2.39 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | -2.8 % |
| 3 months | +6.0 % |
| 6 months | +18.9 % |
| YTD | +16.5 % |
| 1 year | +36.5 % |
| 3 years | +50.7 % |
| 5 years | +183.5 % |
Risk
| 1-year volatility | 28.7 % |
| Beta | 0.30 |
| 5-year max drawdown | -29.1 % |
| Sharpe 1A | 1.09 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.